The Pacific Cancer Research Consortium (PCRC) brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. The PCRC includes Swedish Cancer Institute in Seattle and its former U10 affiliates (the Puget Sound Oncology Consortium), Providence Portland Medical Center in Portland and its former Community Clinical Oncology Program affiliates (the Western Oncology Research Consortium), and Mountain States Tumor Institute in Boise. Under a multiple PI/PD structure, the 3 primary components of the PCRC will define and facilitate the clinical trial and cancer care delivery research agenda across 24 participating components and 14 sub-components in Washington, Oregon, Idaho, Alaska, and California. Each of our primary component sites has decades of experience conducting clinical trials in cancer and plan to participate in all aspect of study design and conduct NCI-approved clinical studies and cancer care delivery research, with particular focus on facilitating the participation of minorities and underserved populations across all study types and settings within our catchment areas, providing bio specimen banking and sharing practices within the participating institutions and with our research bases, and incorporating genomic medicine and targeted therapies into our portfolio of research capabilities. We also plan to build a multicenter infrastructure and research agenda for cancer care delivery research to support the trials proposed by the NCTN, allowing us to participate in the development of novel approaches to CC DR studies.

Public Health Relevance

This joint application and the proposed structure com e from our desire to create the strongest NCORP application from our region that will excel in patient accrual, and foster new and close collaboration between investigators. We believe that our structure will accelerate the translation of knowledge gained from cancer clinical trials into clinical practice and enhance the science, the treatments, and the delivery of care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189953-02
Application #
8902092
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Pearson, Deborah
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
2
Fiscal Year
2015
Total Cost
$1,325,635
Indirect Cost
$68,516
Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
079264420
City
Seattle
State
WA
Country
United States
Zip Code
98122
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952

Showing the most recent 10 out of 33 publications